Please assess the completion status of the following clinical trial:

Trial Title: Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who completed the phase III trial (MT14-KR20GBL309)~* Patients who were capable of understanding and complying with the protocol and have signed the informed consent form voluntarily~Exclusion Criteria:~* Patients who have received other procedures which may affect glabellar lines within 6 months (except of MBA-P01 or BOTOX® treated in phase III trial, MT14-KR20GBL309)~* Female patients who are pregnant or lactating. Female patients of childbearing age who have a plan to get pregnant during the study period.~* Patient who do not use available contraceptive methods (Women of childbearing age should have negative urine pregnancy test results at baseline visit (0 week) prior to the first injection.)~* Patients who are participating in other clinical trials or have participated in other clinical trials 30 days before screening~* Patients who are not eligible for this study based on the judgment of an investigator

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MBA-P01 (Type: EXPERIMENTAL): MBA-P01 will be injected into GL:

Based on this trial design, predict the completion outcome and termination type (if applicable).